Clinical trials: TACE(Transcatheter Arterial Chemoembolization)
Hepatocellular Carcinoma With PVTT
Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis
The treatment for Hepatocellular Carcinoma (HCC) with Portal Vein Tumor Thrombosis (PVTT) is still controversial, and there is no universally agreed protocol for its treatment.
- Trial name
- NCT01350206
- Testing
- hepatic resection, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC)
This is a real world study to determine the short-term efficacy and safety of Elaboration transcatheter arterial chemoembolization (E-TACE) for hepatocellular carcinoma (HCC)
- Trial name
- NCT06023147
- Testing
- E-TACE
- Where
- 27 sites in China
- Volunteers
- 298 people
- Sponsor
- Xuhua Duan
Hepatocellular Carcinoma
SBRT + TACE for Primary Hepatocellular Carcinoma
The purpose of this study is to determine the feasibility and toxicity of combining SBRT and TACE for unresectable HCC and to evaluate the Health Related Quality of Life (HRQL) associated with combined therapy.
- Trial name
- NCT00746655
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Transcatheter Arterial Chemoembolization (TACE)
- Where
- 4 sites in United States
- Sponsor
- University of Pittsburgh
Hepatocellular Carcinoma, Face Cancer
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 6th most common cancer and the third most frequent cause of cancer death worldwide. Hepatic resection (HR) has been the standard treatment modality for HCC aiming at clinical cure.
- Trial name
- NCT01833299
- Testing
- TACE-Sorafenib group, TACE
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
HCC
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
This study will evaluate the efficacy and safety of TACE combined with atezolizumab + bevacizumab in the treatment of unresectable hepatocellular carcinoma, and the treatment patterns of the combination regimen
- Trial name
- CHANCE023 (NCT06024252)
- Testing
- TACE
- Volunteers
- 200 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC
The trial is a multicentre, prospective, randomised controlled, unblinded, parallel-group superiority trial of SBRT versus standard TAE/TACE for the curative treatment of inoperable HCC treated with a TAE/TACE incomplete cycle.
- Trial name
- NCT02323360
- Testing
- SBRT, TACE
- Where
- Italy
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Liver Cancer, Transcatheter Arterial Chemoembolization
Effectiveness of Positioning on Back Pain After TACE Among Patients With HCC
Changing patients' position in the bed after TACE can decrease the level of back pain without increasing the amount of bleeding and hematoma,bring patients some comfort and relieving abdominal bloating, increase patients'…
- Trial name
- NCT03784469
- Testing
- Changing body position in bed
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma Non-resectable
TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
This study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab in patients with unresectable intermediate or advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT04592029
- Testing
- TACE combined with sintilimab and bevacizumab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Small Hepatocellular Carcinoma, Stereotactic Body Radiation Therapy
Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE
The study aims to compare efficacy and adverse reactions of hepatocellular carcinoma participants (≤5cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators…
- Conditions
- Small Hepatocellular Carcinoma, Stereotactic Body Radiation Therapy, Transcatheter Arterial Chemoembolization
- Trial name
- NCT04161287
- Testing
- transcatheter arterial chemoembolization
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Beijing 302 Hospital
Hepatocellular Carcinoma Non-resectable
Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
This is an Open-label, Multicenter, Phase II clinical trial to evaluate the efficacy and safety of Transcatheter arterial chemoembolization (TACE), Lenvatinib combination with Sintilimab (Triple Therapy) sequential radiotherapy…
- Trial name
- NCT06561399
- Testing
- TACE, Lenvatinib combination with Sintilimab sequential radiotherapy
- Where
- 4 sites in China
- Volunteers
- 28 people
- Sponsor
- Fujian Provincial Hospital
Hepatocellular Carcinoma
Transarterial Ethanol Ablation (TEA) Versus Transcatheter Arterial Chemoembolisation (TACE) for Hepatocellular Carcinoma
The current randomized controlled trial comparing LEM and TACE aims to evaluate the safety and efficacy of LEM as compared to TACE for treating patients with unresectable HCC.
- Trial name
- NCT00467974
- Testing
- TEA with LEM, TACE
- Where
- 3 sites in Hong Kong
- Volunteers
- 98 people
- Sponsor
- Chinese University of Hong Kong
Advanced Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma
The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) followed by Sorafenib with TACE alone in patients with advanced hepatocellular carcinoma.
- Trial name
- TACE (NCT02150317)
- Testing
- TACE+Sorafenib, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Liver Metastasis Colon Cancer
TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens
Liver metastasis is the main reason that affects the survival rates of patients with colorectal cancer (CRLM), and is also the main cause of death of those patients.
- Trial name
- DREAM (NCT06071052)
- Testing
- TACE and HAIC Combined With Regorafenib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
To explore the effects of lenvatinib in combination with tislelizumab with or without TACE in patients with hepatocellular carcinoma on survival, disease progression, and medication safety.
- Trial name
- NCT05842317
- Testing
- Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Carcinoma, Hepatocellular
Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
The purpose of this study is to determine if TACE plus Sorafenib will improve outcome in patients with advanced hepatocellular carcinoma (HCC) not amenable to surgery.
- Trial name
- NCT00576056
- Testing
- Sorafenib, TACE
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Pittsburgh
Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion
According to radiology imaging, the patients of HCC are divided into two groups(hypovascular tumor group and moderately vascular tumor group).
- Trial name
- NCT00826384
- Testing
- balloon catheter
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma, Liver Failure
Liver Stiffness Measurement (LSM) in Predicting Progress of Liver Fibrosis After TACE for Hepatocellular Carcinoma
Objective: To evaluate the efficacy of preoperative liver stiffness measurement(LSM) by FibroScan in predicting the progress of liver fibrosis and prognosis after transcatheter arterial chemoembolization (TACE) in hepatocellular…
- Trial name
- NCT03285867
- Testing
- TACE
- Volunteers
- 200 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatocellular Carcinoma
Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma
The aim of this study is to compare the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with the anti-angiogenic targeted drugs and ginsenoside Rg3 versus TACE alone in patients with unresectable…
- Trial name
- NCT04523467
- Testing
- Anti-angiogenic Targeted Drugs, Ginsenoside Rg3, TACE
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis
Irradiation Stent Placement Plus TACE for HCC and PVTT
The study is a multicenter, randomized (1:1), open-label, parallel-arm, Phase 3 clinical trial to evaluate the efficacy and safety of portal irradiation stent placement plus TACE compared to sorafenib plus TACE in patients with…
- Trial name
- NCT03730675
- Testing
- Portal irradiation stent placement, TACE, Sorafenib
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma, Surgery
TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial hepatectomy is still considered as the conventional therapy for HCC.
- Conditions
- Hepatocellular Carcinoma, Surgery, Ablation
- Trial name
- TACE-RFA (NCT01833286)
- Testing
- TACE+RFA, re-resection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University